Risen Pharma Tech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Clinical-stage biotech developing small molecule and siRNA drugs for osteoarthritis, oncology, and Alzheimer's disease with international competitiveness.
OrthopedicsOncologyNeuroscience
Technology Platform
Integrated drug discovery platform combining small molecule design with siRNA therapeutics development, featuring target validation, high-throughput screening, and translational medicine capabilities.
Opportunities
Growth opportunities include expanding their siRNA platform beyond ANGPTL3, advancing combo therapies through TopAlliance collaboration, and leveraging their manufacturing site for future commercialization.
Risk Factors
Key risks include clinical trial failures across multiple therapeutic areas, intense competition in osteoarthritis and Alzheimer's markets, and dependence on partnership strategies for combo therapy development.
Competitive Landscape
Competes with numerous biotechs in osteoarthritis (Flexion Therapeutics), oncology PI3K inhibitors (Novartis, Roche), and Alzheimer's disease (Biogen, Eisai), but differentiates through dual small molecule/siRNA platform and China/US clinical development strategy.